Latest From BlueRock Therapeutics
Bayer's novel 2016 joint venture with the venture capital group Versant Ventures has spawned something like a big pharma, new science start-up, with an open mandate to disrupt drug development through generous endowments in the scarce commodities of freedom, time and patience.
Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create novel gene therapies for cancer, neurological, cardiovascular and autoimmune diseases.
The German group believes it is going to be at the forefront of development in the cell and gene therapy space but is worried that Europe is failing to recognize the value that the pharma industry and its new technologies can create for society.
Companies working on cell and gene therapies and novel approaches to neurological diseases participated in a roundtable discussion during the J.P. Morgan Healthcare Conference about how regulators are supporting novel modalities, which in turn improves investor and partner sentiment.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Company Type
- Parent & Subsidiaries
- BlueRock Therapeutics
- Senior Management
Emile Nuwaysir, PhD, Pres. & CEO
Shane Kovacs, CBO & CFO
Robert Deans, PhD, CTO
Michael Scott, PhD, SVP, Product Dev.
Derek Hei, PhD, SVP, Manufacturing, Quality & Reg.
Joachim Fruebis, PhD, Chief Dev. Officer
- Contact Info
Cambridge, MA 02142
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.